In the next, these subjects are described from the context of the leading procedures in adjuvant therapy of EBC.There were no clinically appropriate improvements as compared to 2011 except for new knowledge and new tips with regard to the procedure with bisphosphonates and denosumab (see section ‘Bisphosphonates and RANKL Antibody Denosumab’).T